Norditropin Flexpro (Somatropin)

Somatropin binds to growth hormone receptors on cell surfaces, triggering the JAK2‑STAT5 pathway. This leads to increased production of insulin‑like growth factor‑1 (IGF‑1) and other growth‑promoting proteins, which stimulate bone growth, protein synthesis, and metabolic functions throughout the body.

The dose of Norditropin Flexpro is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, indication, and IGF‑1 response, and then provides specific administration instructions.

Safety data for somatropin in pregnancy and lactation are limited. It is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk, and the decision should be made by a healthcare professional.

To request Norditropin Flexpro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Norditropin Flexpro is a recombinant somatropin formulation similar in efficacy to other GH products such as Genotropin or Humatrope. Differences may lie in device design, stability profile, and dosing flexibility, but all deliver the same active molecule and are used for the same clinical indications.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep it in the original packaging until use, and discard any vial that has been left at room temperature for longer than the period specified in the label.

Norditropin Flexpro is given as a subcutaneous injection, usually using a pre‑filled pen or syringe. The injection site is rotated among the abdomen, thigh, or upper arm, and the prescriber provides detailed instructions on preparation, dosing, and disposal of sharps.

Serious adverse events include intracranial hypertension, slipped capital femoral epiphysis, new‑onset diabetes or worsening glucose control, severe allergic reactions, and potential tumor recurrence. Patients should be monitored for headaches, visual changes, joint pain, and abnormal blood glucose levels.

Norditropin Flexpro is contraindicated in individuals with active malignancy, known hypersensitivity to somatropin or any excipients, and in patients with uncontrolled diabetes or severe acute illness where growth hormone therapy could be harmful. A healthcare professional must evaluate each case before prescribing.